Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Clinical evidence for growth-hormone secretagogues supplied for research — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-016/5
Series
Evidence synthesis
Version
1.0
Published
26 Jan 2025
Last reviewed
26 May 2025
Next review
26 Nov 2026
Identifier
10.71829/cei.syn.16
Certainty
Very low
Cycle
2025 Q1
Review type
Scoping review
Search executed
29 Oct 2024

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
13 Oct 20240.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
21 May 20251.1Certainty rating revisedThe certainty rating for one outcome was revised following the addition of a contributing study. The rationale is recorded in the certainty assessment section.
26 Dec 20251.2Analysis method changedThe pooling method was changed from a fixed-effect to a random-effects model following observation of between-study heterogeneity exceeding the pre-specified threshold.
14 Feb 20261.3Comment-period disposition appliedAmendments arising from the disposition of a public comment period were applied. Each amendment is traceable to a numbered submission.
16 Jul 20261.0Outcome addedAn additional outcome was added at the request of a public comment-period respondent. The addition is recorded here because it was made after protocol registration and is therefore post hoc.
Current version 1.0, ratified in the 2025 Q1 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
CJC-PH1-ASCENDING05 Oct 2024Refused
CJC-PH1-MULTIDOSE31 Aug 2024No response
GHRP2-JP-DIAGNOSTIC20 Aug 2024Partially supplied
IPA-PH1-GH09 Sep 2024No response
HEX-PH2-ELDERLY06 Sep 2024No response
GHRP6-PH1-GH08 Aug 2024Partially supplied
HEX-PH1-GH11 Sep 2024Supplied on request
SERM-DIAGNOSTIC10 Oct 2024Supplied on request

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.